UPDATE 1-AstraZeneca's Imfinzi gets speedy FDA review for small cell lung cancer

British drugmaker AstraZeneca Plc said on Friday its immunotherapy cancer treatment Imfinzi has been granted a speedy review by the U.S. medicines watchdog for the treatment of a particularly aggressive type of lung cancer.